This database contains 350 studies, archived under the term: "therapeutic use"
Click here to filter this large number of results.
Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses
Objective: In Alzheimer’s disease (AD), rivastigmine has demonstrated statistically significant efficacy versus placebo on cognition and activities of daily living (ADL). The aim of this retrospective analysis was to further evaluate the treatment effects of rivastigmine on individual ADL items.; Methods: This exploratory analysis focused on the Alzheimer’s Disease Cooperative Study Activities of Daily Living […]
Phenserine efficacy in Alzheimer’s disease
Winblad, Bengt,
Giacobini, Ezio,
Frölich, Lutz,
Friedhoff, Lawrence T.,
Bruinsma, Gosse,
Becker, Robert E.,
Greig, Nigel H.
To gather preliminary evidence in Alzheimer’s disease (AD) for the efficacy of phenserine, a non-competitive acetylcholinesterase inhibitor that has independent modulatory effects on amyloid-β generation, a 12-week comparison of patients receiving phenserine (10 and 15 mg BID) or placebo was conducted under double-blind conditions. Patients who completed 12 weeks of the double-blind before others were […]
The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer’s disease
Wiig, E. H.,
Annas, P.,
Basun, H.,
Andreasen, N.,
Lannfelt, L.,
Zetterberg, H.,
Blennow, K.,
Minthon, L.
Objectives: To explore the longitudinal stability of measures of cognition during treatment with acetylcholinesterase inhibitors (AchEI) in patients with Alzheimer’s disease (AD).; Materials and Methods: Cognitive status was measured in a cohort of 60 patients at 6 months after initiation of treatment with AchEI (baseline) and after an additional 6 months of treatment (endpoint). A […]
Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer’s disease trial
Wessels, Alette M.,
Pollock, Bruce G.,
Anyama, Norbert G.,
Schneider, Lon S.,
Lieberman, Jeffrey A.,
Marder, Stephen R.,
Bies, Robert R.
Risperidone has been used to treat behavioral symptoms, such as delusions and agitation, in people with Alzheimer’s disease. The relationship between magnitude and variability of risperidone and 9-hydroxy risperidone exposure and the relationship with time to discontinuation of the medication were explored. Sixty-five subjects from the Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer’s Disease Trial that […]
Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes
Weintraub, Daniel,
Rosenberg, Paul B.,
Drye, Lea T.,
Martin, Barbara K.,
Frangakis, Constantine,
Mintzer, Jacobo E.,
Porsteinsson, Anton P.,
Schneider, Lon S.,
Rabins, Peter V.,
Munro, Cynthia A.,
Meinert, Curtis L.,
Lyketsos, Constantine G.
Background: Depression and antidepressant use are common in Alzheimer disease (AD), but the effect of antidepressant treatment for depression on longer term outcomes is unknown. The authors report the Week-24 outcomes of patients who participated in a 12-week efficacy study of sertraline for depression of AD.; Methods: One hundred thirty-one participants (sertraline = 67, placebo […]
Efficacy of rivastigmine on executive function in patients with Parkinson’s disease dementia
Background and Objective: Rivastigmine is approved in the USA for the treatment of mild to moderate Alzheimer’s disease and Parkinson’s disease dementia (PDD). Executive function (EF) deficits are a core symptom of PDD. The current objective was to investigate the effects of rivastigmine capsules versus placebo on EF in PDD, focusing on secondary outcome measures […]
Sertraline for the treatment of depression in Alzheimer disease
Rosenberg, Paul B.,
Drye, Lea T.,
Martin, Barbara K.,
Frangakis, Constantine,
Mintzer, Jacobo E.,
Weintraub, Daniel,
Porsteinsson, Anton P.,
Schneider, Lon S.,
Rabins, Peter V.,
Munro, Cynthia A.,
Meinert, Curtis L.,
Lyketsos, Constantine G.
Objective: Depression is common in Alzheimer disease (AD), and antidepressants are commonly used for its treatment, however, evidence for antidepressant efficacy in this population is lacking. The authors conducted a multicenter, randomized, placebo-controlled trial titled “Depression in Alzheimer’s Disease-2” to assess the efficacy and tolerability of sertraline for depression in AD.; Methods: One hundred thirty-one […]
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial
Quinn, Joseph F.,
Raman, Rema,
Thomas, Ronald G.,
Yurko-Mauro, Karin,
Nelson, Edward B.,
van Dyck, Christopher,
Galvin, James E.,
Emond, Jennifer,
Jack, Clifford R., Jr.,
Weiner, Michael,
Shinto, Lynne,
Aisen, Paul S
Context: Docosahexaenoic acid (DHA) is the most abundant long-chain polyunsaturated fatty acid in the brain. Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology.; Objective: To determine if supplementation with DHA slows cognitive and functional decline […]
Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease
Penner, Jacob,
Rupsingh, Raul,
Smith, Matthew,
Wells, Jennie L.,
Borrie, Michael J.,
Bartha, Robert
Galantamine is a cholinesterase inhibitor and allosteric potentiating ligand modulating presynaptic nicotinic acetylcholine receptors that is used in the treatment of Alzheimer disease (AD). The purpose of this study was to determine if galantamine treatment would result in detectable hippocampal metabolite changes that correlated with changes in cognition, as measured by the Mini-Mental State Examination […]